The FDA finalized the May 4, 2016, draft guidance for special protocol assessments (SPAs), a document that will overwrite a 2002 guidance by the same name. The guidance is intended to facilitate assessments of the design of pivotal studies of drugs and biologics, and the FDA said the final represents edits to the draft in order to "improve clarity and readability."